SecBot SecBot
PRESS-RELEASE ·Filed Aug 20, 2026

EVAX

Evaxion
NEUTRAL
Impact 4/10
Horizonmonths Processed2mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor the ESMO 2026 presentation in October for EVX-01 three-year data, which is the key near-term catalyst. Cash runway into H2 2027 reduces near-term dilution risk, but the company remains pre-revenue and will need additional capital before then. Partnership discussions are ongoing but unconfirmed.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.28
T+0 close · Aug 20, 2026 · via day close
Latest settled
−16.46%
T+60 · $2.74
Vs SPY
−15.38%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 20 $3.28entry
  2. T+1 · 3mo ago +0.91%α +0.51% · $3.31
  3. T+5 · 3mo ago −3.96%α −5.08% · $3.15
  4. T+20 · 2mo ago −0.30%α −0.30% · $3.27
  5. T+60 · 4d ago −16.46%α −15.38% · $2.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion reported Q2 2026 net loss of $3.7M, in line with expectations and improved from $4.8M a year ago, with cash of $14.0M funding operations into H2 2027. The company highlighted pipeline progress including upcoming ESMO data for EVX-01 and preclinical advances for EVX-04 and EVX-05, but reported zero revenue and a GAAP EPS of -$0.01, which was a 4900% miss vs the -$0.01 consensus estimate due to a rounding artifact on a tiny base. The filing is neutral as the financials were as expected and the EPS miss is mechanical on a pre-revenue biotech with minimal analyst coverage, while pipeline catalysts are forward-looking and uncertain.

Key Financial Metrics

EPS
−$0.01
est −$0.01 · 0.0%
Revenue
$0.00
est $0.00
Rating
in line

Key Facts

  • Q2 2026 net loss of $3.7M vs $4.8M in Q2 2025, in line with expectations
  • Cash and cash equivalents of $14.0M as of June 30, 2026, providing runway into H2 2027
  • R&D expenses of $2.3M, G&A of $1.5M, both aligned with Q1 2026
  • Zero revenue reported; GAAP EPS of -$0.01 vs consensus of -$0.01 (miss of -4900% is a mechanical artifact of a tiny base)
  • Pipeline catalysts: three-year EVX-01 data at ESMO 2026, preclinical progress on EVX-04 and EVX-05, and EVX-V1 CMV vaccine data

Financial Impact

Net loss improved 22% YoY to $3.7M; cash burn $4.4M in Q2 2026; no revenue generated

net losscashR&D expenses

Risk Factors

  • Pre-revenue clinical-stage biotech with no approved products
  • Cash runway only into H2 2027; likely need for additional financing
  • Pipeline candidates are early-stage (preclinical/Phase 2) with high clinical risk
  • EPS miss of -4900% is a rounding artifact but may spook algorithmic traders

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3348249

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 20, 2026